Push the Envelope

Good morning Folks, 
We had a slight pullback yesterday as volatility started to creep back in.

The IBB continues to struggle as another Biotech was targeted by Citron.  MNK and VRX are both very volatile and are likely to stay that way for the near future. 

Gold had a little bounce yesterday as the dollar strength took a breather but I would not expect that trend to last. 

IEA  announced that oil could get back to 80 a barrel by 2020 and that there will continue to be deep investment cuts in the sector.

Volatility is a very good thing for short term trading but it can also be very erratic so size your positions accordingly. 


Stocks on my radar premarket

Bullish and may have a swing or lottos in play

Cautiously optimistic

Very Cautious may even present a short opportunity .

SPHS	Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint

Low floater going to be a gapper 1 Dolla Roll also going to need cash soon could be a runner look for volume but don't chase it 

UPDATE forget the 1 dolla holla its gapping over 3 Be careful but it could be a crazy runner look for a good entry setup and have a defined strategy for risk reward 

SCLN	SciClone Sees FY15 Rev. Remains Unchanged At $153-$158M
04:22:38pm 11/09/15 SCLN	SciClone Raises FY15 EPS From $0.73-$0.77 To $0.93-$0.97
04:21:55pm 11/09/15 SCLN	SciClone Reports Q3 EPS $0.26, Rev. $42.9M vs. Est. $40.61M

Another gapper low floater with a nice balance sheet gapping right into resistance at the 10 dolla holla 

PACB	Betavilles Ben Harrington Speculates Pacific Biosciences May Be A M&A Target For Roche Holdings

Stock held up well in yesterdays market sloppy flag but could get an 8 roll and maybe there is some truth to the takeover rumor but it can be a very tricky trader 

STRP	Nikos Hecht Reports 9.2% Passive Stake in Straight Path Communications

This was a target of one of those short reports and could have a nice snapback Day trade only for me 

(NASDAQ: BLCM), which rose more than 14 percent after the bell rang. For the third quarter of 2015, the company reported a net loss

Gapped last night could go either way had a run up into earnings may set up to fade 

OPK	OPKO Health Reports Q3 Sales $143M vs $133M Est., $0.25 vs $(0.11) in Same Qtr. Last Year

One of the FEW Biotech stocks that I hold in my long term hold account Gapping over the ten dolla holla could see some follow through 

TUBE	TubeMogul Sees Q4 Sales $51M-$53M vs $50.9M Est., Adj. EBITDA $(2M)-$0M; Sees FY15 Sales $173M-$175M vs $165M Est.

Insider buys @ 11 and change popping premarket could continue if  it can hold over 13

FTK	Hearing John Hempton/Bronte Capital Negative on Flotek

Company plans to address some negative comments made about their operation yesterday Could get a snapback